-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Fc6+Jnb6wwREBaZYQdWk5Y9yG+69Bn1hpv+RdFhesHsmdleM0GIARCBlRKVNlX61 kIbuWijKJMDqOw10udDUQA== 0001317757-11-000007.txt : 20110228 0001317757-11-000007.hdr.sgml : 20110228 20110228160333 ACCESSION NUMBER: 0001317757-11-000007 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20110224 FILED AS OF DATE: 20110228 DATE AS OF CHANGE: 20110228 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Arkowitz David CENTRAL INDEX KEY: 0001296999 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-10865 FILM NUMBER: 11646089 MAIL ADDRESS: STREET 1: C/O IDENIX PHARMACEUTICALS, INC. STREET 2: 60 HAMPSHIRE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AMAG PHARMACEUTICALS INC. CENTRAL INDEX KEY: 0000792977 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 042742593 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 100 HAYDEN AVENUE CITY: LEXINGTON STATE: MA ZIP: 02140 BUSINESS PHONE: 6174972070 MAIL ADDRESS: STREET 1: 100 HAYDEN AVENUE CITY: LEXINGTON STATE: MA ZIP: 02140 FORMER COMPANY: FORMER CONFORMED NAME: ADVANCED MAGNETICS INC DATE OF NAME CHANGE: 19920703 4 1 primary_doc.xml PRIMARY DOCUMENT X0303 4 2011-02-24 0 0000792977 AMAG PHARMACEUTICALS INC. AMAG 0001296999 Arkowitz David C/O AMAG PHARMACEUTICALS, INC. 100 HAYDEN AVENUE LEXINGTON MA 02421 0 1 0 0 EVP, Chief Financial Officer Common Stock 2011-02-24 4 C 0 1875 A 3011 D Common Stock 2011-02-24 4 S 0 500 17.1 D 2511 D Common Stock 2011-02-24 4 S 0 2205 17.06 D 306 D Restricted Stock Unit 2011-02-24 4 C 0 1875 A Common Stock 1875 1875 D The shares were acquired by the reporting person as a result of the partial vesting of a restricted stock unit grant described below. Not applicable. The sales reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Each restricted stock unit represents a contingent right to receive one share of common stock. Grant of restricted stock unit pursuant to the AMAG Pharmaceuticals, Inc. Second Amended and Restated 2007 Equity Incentive Plan. This grant vests in four equal installments on February 24, 2011, February 24, 2012, February 24, 2013 and February 24, 2014. Joseph L. Farmer, attorney-in-fact 2011-02-28 -----END PRIVACY-ENHANCED MESSAGE-----